MergerJun 8, 2026, 07:31 AM
Standard BioTools to Merge with Treeline; Combined Co. to have $900M+ Cash
AI Summary
Standard BioTools Inc. and Treeline Biosciences, Inc. announced a definitive merger agreement in an all-stock transaction. The combined entity, to be named Treeline Biosciences and trade as "TRLN" on Nasdaq, will be led by Treeline CEO Josh Bilenker, MD. It is expected to be well-capitalized with over $900 million in cash at closing, providing a runway into 2029, and will advance a deep pipeline of small molecule inhibitors, protein degraders, and targeted therapy antibody-drug conjugates. Standard BioTools is also exploring strategic options, including divestitures, for its Mass Cytometry and Microfluidics businesses.
Key Highlights
- Standard BioTools and Treeline Biosciences to merge in an all-stock transaction.
- Combined company will operate as Treeline Biosciences, trading as "TRLN" on Nasdaq.
- Josh Bilenker, MD, Treeline CEO, will lead the combined company.
- Combined company expected to have over $900 million in cash at closing, providing runway into 2029.
- Treeline's pipeline includes three Phase 1 programs with clinical data readouts beginning in 2027.
- Four additional programs are expected to enter the clinic between 2026 and 2028.
- Pre-merger Standard BioTools stockholders expected to own approximately 16% of the combined company.
- Standard BioTools is exploring divestment options for its Mass Cytometry and Microfluidics businesses.
Price Impact
More from LAB